{"name":"Janssen Infectious Diseases BVBA","slug":"janssen-infectious-diseases-bvba","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Aged RPV-LA","genericName":"Aged RPV-LA","slug":"aged-rpv-la","indication":"Other","status":"phase_1"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Rilpivirine (RPV)","genericName":"Rilpivirine (RPV)","slug":"rilpivirine-rpv","indication":"Treatment of HIV-1 infection in treatment-naive adults","status":"phase_3"}]}],"pipeline":[{"name":"Aged RPV-LA","genericName":"Aged RPV-LA","slug":"aged-rpv-la","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Rilpivirine (RPV)","genericName":"Rilpivirine (RPV)","slug":"rilpivirine-rpv","phase":"phase_3","mechanism":"Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks the replication of HIV-1 by binding to the reverse transcriptase enzyme.","indications":["Treatment of HIV-1 infection in treatment-naive adults"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNV2t1NVRubEtnUU91NE03SmpkOEJfYmk4U09OLTNmNGtXMGhQS3A0SFhEenJYVjVCQzFtX0drcUVPVmxzaG00YmFiSnh6MDhmQlRoRWtnQXp2WE50MHRJQjJwc2lEcHpCeTBMQ3ZDVmFCTDJ4LWRxLXp1SV9UR0lKRG5aeUNJZ1owYTBJNkphMTBOWldHVVBwUThfLTdhZTlZQ1owcFlaVnFmUzlxYmNTRlhoN0M1dw?oc=5","date":"2018-06-21","type":"pipeline","source":"Agency for Science, Technology and Research","summary":"Spotlight: How to turn failures into success - Agency for Science, Technology and Research","headline":"Spotlight: How to turn failures into success - Agency for Science, Technology and Research","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}